Raltegravir: The first HIV integrase inhibitor
References (49)
- et al.
Raltegravir with optimized background therapy for resistant HIV-1 infection
N Engl J Med.
(2008) - HIV/AIDS Surveillance...
- US Food and Drug Administration. Drugs used in the treatment of HIV...
- et al.
HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins
AIDS Rev.
(2005) - et al.
The hunt for HIV-1 integrase inhibitors
AIDS Patient Care STDS.
(2006) - et al.
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
Science.
(2000) - et al.
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
J Med Chem.
(2008) - Summa V, Pace P, Petrocchi A, et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in...
- Isentress [package...
- Raltegravir [scientific...
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
Clin Pharmacol Ther.
(2008)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
J Acquir Immune Defic Syndr.
(2006)
Metabolism and disposition in humans of raltegravir (MK-0518), an anti- AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme
Drug Metab Dispos.
(2007)
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
AIDS.
(2007)
Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study
J Acquir Immune Defic Syndr.
(2007)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial
Lancet.
(2007)
Cited by (109)
Control of metalloenzyme activity using photopharmacophores
2024, Coordination Chemistry ReviewsAuthentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS
2023, Privileged Scaffolds in Drug DiscoveryHIV integrase inhibitors that inhibit strand transfer interact with RAG1 and hamper its activities
2021, International ImmunopharmacologyCitation Excerpt :It was the first HIV integrase inhibitor to be approved and was sold under the brand name Isentress®. It belongs to diketo acid class of inhibitors and was seen to be metabolized through glucuronidation [24]. Sato and co-workers in 2006 showed that 4-quinolone-3-carboxylic acids are an alternative to diketo acids, leading to the discovery of Elvitegravir (GS-9137) (Fig. 3), which could efficiently inhibit HIV-1 integrase [25].
Copyright © 2008 Published by Elsevier Inc.